% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kemp:294315,
      author       = {T. J. Kemp and G. Panicker and C. Eklund and J. Nie and Y.
                      Wang and S. Beddows and P. Rigsby and W. Huang and J.
                      Dillner and E. R. Unger and L. A. Pinto and D. E. Wilkinson},
      collaboration = {c. s. participants},
      othercontributors = {P. Licciardi and Z. Q. Toh and M. Müller$^*$ and T. M. C.
                          Rajanathan and S. Li and N. Xia and G. Liu and C. Zhou and
                          L. Zhou and N. Xu and K. Panwar and D. Galloway and J.
                          Carter},
      title        = {{WHO} {I}nternational {S}tandards for antibodies to {HPV}6
                      {HPV}11 {HPV}31 {HPV}33 {HPV}45 {HPV}52 and {HPV}58.},
      journal      = {npj vaccines},
      volume       = {9},
      number       = {1},
      issn         = {2059-0105},
      address      = {[London]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2024-02148},
      pages        = {165},
      year         = {2024},
      abstract     = {Previously established World Health Organization (WHO)
                      International Standards (IS) for anti-HPV16 and HPV18
                      antibodies are used to harmonize results across human
                      papillomavirus (HPV) serology assays. Here, we present an
                      international collaborative study to establish ISs for
                      antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174),
                      HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52
                      (19/296) and HPV58 (19/300). The candidate standards were
                      prepared using sera from naturally infected individuals.
                      Each candidate was shown to be monospecific for reactivity
                      against its indicated HPV type except for the HPV11
                      candidate, which was also reactive against other types.
                      Expression of antibody levels relative to the relevant
                      candidate IS reduced inter-laboratory variation allowing
                      greater comparability between laboratories. Based on these
                      results, the WHO Expert Committee on Biological
                      Standardization established each of the 7 candidates as the
                      1st IS for antiserum to its indicated HPV type for use in
                      the standardization of HPV pseudovirion-based neutralization
                      and antibody-binding assays.},
      cin          = {D335},
      ddc          = {610},
      cid          = {I:(DE-He78)D335-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39256440},
      pmc          = {pmc:PMC11387505},
      doi          = {10.1038/s41541-024-00949-2},
      url          = {https://inrepo02.dkfz.de/record/294315},
}